Travere Therapeutics
TVTX
128 hedge funds and large institutions have $1.21B invested in Travere Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 39 reducing their positions, and 18 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $9.99M
10% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 39
10% more capital invested
Capital invested by funds: $1.1B → $1.21B (+$112M)
2.2% more ownership
Funds ownership: 103.36% → 105.56% (+2.2%)
1% less funds holding
Funds holding: 129 → 128 (-1)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$15.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$11.5M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$10M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$9.35M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$8.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$7.89M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.37M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$5.82M |
| 4 |
BA
Boston Advisors
Boston,
Massachusetts
|
-$3.41M |
| 5 |
BC
Broadfin Capital
New York
|
-$3.16M |
TVTX Hedge Fund Activity: Q3 2018 in Review
128 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2018, worth a combined $1.21B — up 10% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TVTX and 17 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 43 added.
The largest buyer was Invesco, adding an estimated $15.5M. The largest seller was Jennison Associates, cutting an estimated $7.89M.
- 128 institutional investors held Travere Therapeutics (TVTX) as of Q3 2018, down from 129 in Q2 2018.
- Funds reported $1.21B of Travere Therapeutics stock for Q3 2018, up 10% quarter-over-quarter.
- 17 funds opened new Travere Therapeutics positions in Q3 2018 and 18 closed out, a net change of -1 holder.
- The largest Travere Therapeutics buyer in Q3 2018 was Invesco, an estimated $15.5M added.
- The largest Travere Therapeutics seller in Q3 2018 was Jennison Associates, an estimated $7.89M sold.
Based on aggregated 13F filings for Q3 2018.